| nivolumab based treatment |
| nivolumab alone | nivolumab plus SoC |
| mNSCLC - L1 - all population 5 | | |
| mNSCLC - L1 - EGFR mutant | | |
| mNSCLC - L1 - PDL1 negative 1 | | |
| mNSCLC - L1 - PDL1 positive 14 | | |
| mNSCLC - L1 - TMB>10Mb 1 | | |
| non squamous cell - mNSCLC - L1 | | |
| non squamous - mNSCLC - L1 - all population 3 | | |
| non squamous - mNSCLC - L1 - PDL1 positive | | |
| non squamous - mNSCLC - L1 - Wild Type (WT) 6 | | |
| squamous cell - mNSCLC - L1 | | |
| squamous - mNSCLC - L1 - all population 4 | | |
| squamous - mNSCLC - L1 - PDL1 positive | | |
| squamous - mNSCLC - L1 - Wild Type (WT) | | |